
## Sarah Townsend

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5655583/publications.pdf Version: 2024-02-01



SADAH TOWNSEND

#	Article	IF	CITATIONS
1	The lysyl oxidase like 2/3 enzymatic inhibitor, PXSâ€5153A, reduces crosslinks and ameliorates fibrosis. Journal of Cellular and Molecular Medicine, 2019, 23, 1759-1770.	3.6	76
2	Systematic review: the natural history of alphaâ€1 antitrypsin deficiency, and associated liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 877-885.	3.7	67
3	Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. Expert Review of Gastroenterology and Hepatology, 2018, 12, 745-747.	3.0	10
4	Rescue from liver transplantation: TIPSS and thrombectomy successfully treat a case of acute Budd–Chiari syndrome complicated by portal vein thrombosis. BJR case Reports, 2017, 3, 20160059.	0.2	1
5	Editorial: liver transplantation in patients with nonâ€alcoholic fatty liver disease and obesity. Alimentary Pharmacology and Therapeutics, 2017, 46, 459-460.	3.7	1
6	Review article: new treatments in nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 494-507.	3.7	50
7	Editorial: optimising nonâ€invasive screening for advanced liver fibrosis in NAFLD. Alimentary Pharmacology and Therapeutics, 2017, 46, 899-900.	3.7	0
8	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156.	6.9	61
9	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data metaâ€analysis of the LEAD program. Alimentary Pharmacology and Therapeutics, 2013, 37, 234-242.	3.7	204
10	Pathogenesis of non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 71-83.	0.5	581